What is GT Biopharma's market cap?

GT Biopharma (GTBP) has a market capitalization of $12.0M and trades on NASDAQ.

Who are GT Biopharma's competitors?

GT Biopharma's key competitors include ImmunityBio, Inc. Common Stock, Bolt Biotherapeutics, Inc. Common Stock, IN8bio, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does GT Biopharma partner with?

GT Biopharma's notable partners include University of Minnesota, Cytovance Biologics, Inc., Bristol Capital, LLC, and others.

Where is GT Biopharma headquartered?

GT Biopharma is headquartered in United States of America and employs approximately 2 people. It has been publicly traded since 2021.

GT Biopharma

GTBP

GT Biopharma Inc. is a clinical-stage biopharmaceutical company specializing in the development of novel immuno-oncology therapeutics.

Market cap

$12.05M+84.1%

Table of contents

Earnings

Q1 2026 report

May 15, 2026

EPS-$0.11Miss by $0.03

Read the full report

Next report

Aug 13, 2026 (In 2 weeks)

EPS estimate-$0.08

Competitors

By market cap

ImmunityBio, Inc.$7.3B+213%

Immunome$2.6B+171%

Tevogen Bio Holdings, Inc.$23.5M-88.8%

GT Biopharma$12.0M+75.3%

IN8bio$11.4M+41.0%

Bolt Biotherapeutics, Inc.$7.6M-36.8%

LIM

Liminatus Pharma, Inc. Class A Common Stock$6.9M-96.8%

Soligenix, Inc.$5.4M+28.4%

By revenue growth

ImmunityBio, Inc.+352%

Immunome-63.3%

By net margin

ImmunityBio, Inc.-606.15%+704pp

Immunome-5,593.85%-3,719pp

Profile

GT Biopharma Inc. is a clinical-stage biopharmaceutical company specializing in the development of novel immuno-oncology therapeutics. The company utilizes its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager platforms to create fusion proteins that activate a patient's natural killer cells to target and eliminate cancer or virus-infected cells. Its core value proposition lies in providing a potentially safer alternative to T-cell immunotherapies by reducing neurological complications and cytokine release syndrome.

Competitive position

GT Biopharma is an early-stage innovator in the NK cell engager space, leveraging a proprietary camelid nanobody platform to enhance therapeutic potency and safety over traditional T-cell therapies.

GeographiesUnited States, Global

Customer segmentsOncology patients, Biopharmaceutical companies, Research institutions

Business modelResearch and development, IP licensing, Clinical-stage drug development

SuppliersContract manufacturing organizations, Academic research institutions, Raw material suppliers for biologics, Clinical trial sites

CustomersBiopharmaceutical collaborators, Hospitals and oncology centers, Specialty pharmacies

CountryUnited States of America

Listed2021

Employees2.0

CEOMichael Martin Breen

SectorHealthcare

IndustryBiotechnology

Websitegtbiopharma.com

FilingsSEC EDGAR

Questions, answered.

What is GT Biopharma's market cap?: GT Biopharma (GTBP) has a market capitalization of $12.0M and trades on NASDAQ.
Who are GT Biopharma's competitors?: GT Biopharma's key competitors include ImmunityBio, Inc. Common Stock, Bolt Biotherapeutics, Inc. Common Stock, IN8bio, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does GT Biopharma partner with?: GT Biopharma's notable partners include University of Minnesota, Cytovance Biologics, Inc., Bristol Capital, LLC, and others.
Where is GT Biopharma headquartered?: GT Biopharma is headquartered in United States of America and employs approximately 2 people. It has been publicly traded since 2021.